Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).
Han‐Bo Zhang, Jeffrey Graham(University of Calgary), Aaron R. Hansen(Princess Margaret Cancer Centre), Naveen S. Basappa, Rodney H. Breau(University of Ottawa), Isaiah Joy(University of Alberta), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Eric Winquist(Western University), Frédéric Pouliot(Université Laval), Georg A. Bjarnason(Sunnybrook Health Science Centre), Sunita Ghosh(Tata Memorial Hospital), Lori Wood(Dalhousie University), Vincent Castonguay(Centre hospitalier universitaire de Québec), Christian Kollmannsberger(BC Cancer Agency), Daniel Yick Chin Heng(University of Calgary), Anil Kapoor(People’s University)
Cited by 2
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
|European Urology|2008|617
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline
|The Journal of Urology|2019|482